Mereo Biopharma (MREO) news

Zydus Lifesciences - Sentynl Therapeutics and Mereo Biopharma announce option and license agreement

Sentynl Therapeutics, a U.S.-based biopharmaceutical company and wholly-owned subsidiary of Zydus Lifesciences Limited, has entered into an option and license agreement with Mereo BioPharma Group plc for the U.S. commercial and global manufacturing rights to alvelestat, a potential first-in-class…

Mereo Biopharma Q2 EPS USD -0.01

Mereo BioPharma Group plc (NASDAQ: MREO) reported a net loss of $14.6 million for the second quarter ended June 30, 2025, translating to an EPS of -$0.01 . This represents a slight increase in the net loss compared to $12.3 million in the same period in 2024. The loss was primarily driven by a $5.4…

Mereo Biopharma Group - cash and cash equivalents of $30.10 mln at June 30, 2026 expected to fund operations into late-2027

Mereo Biopharma Group plc (NASDAQ: MREO) reported cash and cash equivalents of $36.2 million as of March 31, 2026, a decrease from $41.0 million as of December 31, 2025. The company continues to expect that its current cash position will support operations through mid-2027, covering key clinical…

Mereo Biopharma Q2 operating income USD -7.03 million

Mereo BioPharma Group plc (NASDAQ: MREO) reported an operating loss of $7.03 million for the second quarter of 2025, reflecting ongoing investment in its clinical-stage pipeline and research and development activities. The company’s net loss for the quarter was $14.6 million, compared to $12.3…

Sentynl Therapeutics - Sentynl and Mereo enter option and license agreement for Alvelestat in AATD-LD